Even Better Hep C Outcome with Vertex’s Quad Combo
Share
Follow Us
Vertex 4-drug hepatitis C combo shows promise
Source: reuters // Reuters
* Treatment combines VX-222, Incivek and 2 older drugs
* Half of patients on treatment rid of virus in 12 weeks
* Vertex shares fall 0.6 percent (Adds analyst comment, safety details, background, updates shares)
CHICAGO, July 26 (Reuters) – As many as half of hepatitis C patients in a small midstage trial who received a four-drug combination, including two Vertex Pharmaceuticals medicines, were able to stop treatment after just 12 weeks, according to interim results from the study.
Vertex on Tuesday released preliminary results of the trial, which added the company’s experimental oral drug VX-222 to its recently approved Incivek pill and the traditional standard treatments of pegylated interferon and ribaviron.
Continue reading this entire article:
http://www.trust.org/item/20110726173407-3r5gj/
